Angiogenesis and Ovarian Cancer: What Potential Do Different Subtypes of Circulating Endothelial Cells Have for Clinical Application?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Jun 19

PMID 38892471

Authors

Du-Bois Asante

Domenico Tierno

Michael Woode

Bruna Scaggiante

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) remains the most fatal disease of gynaecologic malignant tumours. The neovasculature in the tumour microenvironment principally comprises endothelial cells. Haematogenous cancer metastases are significantly impacted by tumour neovascularisation, which predominantly depends on the tumour-derived endothelial vasculogenesis. There is an urgent need for biomarkers for the diagnosis, prognosis and prediction of drug response. Endothelial cells play a key role in angiogenesis and other forms of tumour vascularisation. Subtypes of circulating endothelial cells may provide interesting non-invasive biomarkers of advanced OC that might have the potential to be included in clinical analysis for patients' stratification and therapeutic management. In this review, we summarise the reported studies on circulating endothelial subtypes in OC, detailing their isolation methods as well as their potential diagnostic, prognostic, predictive and therapeutic utility for clinical application. We highlight key biomarkers for the identification of circulating endothelial cell subtypes and their targets for therapies and critically point out future challenges.

References

Donnem T, Reynolds A, Kuczynski E, Gatter K, Vermeulen P, Kerbel R . Non-angiogenic tumours and their influence on cancer biology. Nat Rev Cancer. 2018; 18(5):323-336. DOI: 10.1038/nrc.2018.14. View

Lin P, Gires O, Wang D, Li L, Wang H . Comprehensive in situ co-detection of aneuploid circulating endothelial and tumor cells. Sci Rep. 2017; 7(1):9789. PMC: 5575124. DOI: 10.1038/s41598-017-10763-7. View

Onyeisi J, Pernambuco Filho P, Mesquita A, de Azevedo L, Nader H, Lopes C . Effects of syndecan-4 gene silencing by micro RNA interference in anoikis resistant endothelial cells: Syndecan-4 silencing and anoikis resistance. Int J Biochem Cell Biol. 2020; 128:105848. DOI: 10.1016/j.biocel.2020.105848. View

Zhang L, Zhang X, Liu Y, Zhang T, Wang Z, Gu M . PD-L1 aneuploid circulating tumor endothelial cells (CTECs) exhibit resistance to the checkpoint blockade immunotherapy in advanced NSCLC patients. Cancer Lett. 2019; 469:355-366. DOI: 10.1016/j.canlet.2019.10.041. View

Beerepoot L, Mehra N, Vermaat J, Zonnenberg B, Gebbink M, Voest E . Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol. 2003; 15(1):139-45. DOI: 10.1093/annonc/mdh017. View

Rabascio C, Muratori E, Mancuso P, Calleri A, Raia V, Foutz T . Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004; 64(12):4373-7. DOI: 10.1158/0008-5472.CAN-04-0265. View

Schilder R, Sill M, Lankes H, Gold M, Mannel R, Modesitt S . A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study. Gynecol Oncol. 2013; 129(1):86-91. PMC: 3712785. DOI: 10.1016/j.ygyno.2013.01.006. View

Zhang S, Cheng C, Lin Z, Xiao L, Su X, Zheng L . The global burden and associated factors of ovarian cancer in 1990-2019: findings from the Global Burden of Disease Study 2019. BMC Public Health. 2022; 22(1):1455. PMC: 9339194. DOI: 10.1186/s12889-022-13861-y. View

Kraan J, Sleijfer S, Foekens J, Gratama J . Clinical value of circulating endothelial cell detection in oncology. Drug Discov Today. 2012; 17(13-14):710-7. DOI: 10.1016/j.drudis.2012.01.011. View

10.

Alvero A, Fu H, Holmberg J, Visintin I, Mor L, Marquina C . Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells. 2009; 27(10):2405-13. PMC: 2783765. DOI: 10.1002/stem.191. View

11.

Priya S, Nagare R, Sneha V, Sidhanth C, Bindhya S, Manasa P . Tumour angiogenesis-Origin of blood vessels. Int J Cancer. 2016; 139(4):729-35. DOI: 10.1002/ijc.30067. View

12.

Asante D, Mohan G, Acheampong E, Ziman M, Calapre L, Meniawy T . Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients. Sci Rep. 2023; 13(1):2552. PMC: 9925814. DOI: 10.1038/s41598-023-29416-z. View

13.

Jakobsson L, Franco C, Bentley K, Collins R, Ponsioen B, Aspalter I . Endothelial cells dynamically compete for the tip cell position during angiogenic sprouting. Nat Cell Biol. 2010; 12(10):943-53. DOI: 10.1038/ncb2103. View

14.

Su Y, Gao L, Teng L, Wang Y, Cui J, Peng S . Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways. J Transl Med. 2013; 11:132. PMC: 3687679. DOI: 10.1186/1479-5876-11-132. View

15.

Gao D, Nolan D, McDonnell K, Vahdat L, Benezra R, Altorki N . Bone marrow-derived endothelial progenitor cells contribute to the angiogenic switch in tumor growth and metastatic progression. Biochim Biophys Acta. 2009; 1796(1):33-40. PMC: 3649840. DOI: 10.1016/j.bbcan.2009.05.001. View

16.

Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, Bertolini F . Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood. 2001; 97(11):3658-61. DOI: 10.1182/blood.v97.11.3658. View

17.

Su Y, Zheng L, Wang Q, Bao J, Cai Z, Liu A . The PI3K/Akt pathway upregulates Id1 and integrin α4 to enhance recruitment of human ovarian cancer endothelial progenitor cells. BMC Cancer. 2010; 10:459. PMC: 2940800. DOI: 10.1186/1471-2407-10-459. View

18.

Ostrand-Rosenberg S, Horn L, Haile S . The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity. J Immunol. 2014; 193(8):3835-41. PMC: 4185425. DOI: 10.4049/jimmunol.1401572. View

19.

Alix-Panabieres C, Marchetti D, Lang J . Liquid biopsy: from concept to clinical application. Sci Rep. 2023; 13(1):21685. PMC: 10709452. DOI: 10.1038/s41598-023-48501-x. View

20.

Rowand J, Martin G, Doyle G, Miller M, Pierce M, Connelly M . Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A. 2007; 71(2):105-13. DOI: 10.1002/cyto.a.20364. View